

Press Release

Gerresheimer AG
Klaus-Bungert-Strasse 4
40468 Düsseldorf
Germany

April 26, 2017

Jens Kürten
Group Senior Director Communication & Marketing
Phone +49 211 6181-250
Telefax +49 211 6181-241
E-Mail j.kuerten@gerresheimer.com
Internet www.gerresheimer.com

Annual General Meeting of Gerresheimer AG approves dividend increase to EUR 1.05 per share

- **Dividend increased for sixth time in succession to EUR 1.05 per share**
- **All shareholder representatives on Supervisory Board reelected**
- **Dr. Axel Herberg reelected as Chairman of the Supervisory Board**

Duesseldorf, April 26, 2017 – A dividend of EUR 1.05 per share was approved at the Annual General Meeting of Gerresheimer AG held today in Duesseldorf. The MDAX-listed Group manufactures glass and plastic pharma and cosmetics packaging together with products for safe and simple drug delivery such as insulin pens, inhalers and syringes.

“Gerresheimer has made further strides in the last year and improved its position. Having sharpened our focus on our core business, we have come closer to fulfilling our vision—to become the leading global partner for enabling solutions that improve health and well-being. Gerresheimer will continue to successfully pursue its path of sustainable growth. Accordingly, we proposed raising the dividend to EUR 1.05 per share, marking the sixth such increase in a row. The increase was voted through by a large majority at today’s Annual General Meeting,” said Uwe Röhrhoff, Chief Executive Officer of Gerresheimer AG, summing up at the Annual General Meeting.

The dividend has been increased by 23.5% to EUR 1.05 per dividend-entitled share. A dividend of EUR 0.85 per share was distributed in the prior year. The dividend will be paid out on May 2, 2017.

A large majority voted in favor of the resolution formally approving the acts of the Management Board and Supervisory Board in financial year 2016. Deloitte GmbH Wirtschaftsprüfungsgesellschaft, Duesseldorf, was elected as auditor for financial year 2017.

The Annual General Meeting also adopted a resolution on the creation of new authorized capital with the possibility to exclude shareholders’ subscription rights as well as on a corresponding amendment to section 4 (4) of the Articles of Association. Furthermore, the Annual General Meeting adopted a new authorization to issue convertible bonds or warrant bonds (or combinations of such instruments) with the possibility

Press Release

Gerresheimer AG
Klaus-Bungert-Strasse 4
40468 Düsseldorf
Germany

April 26, 2017

Jens Kürten
Group Senior Director Communication & Marketing
Phone +49 211 6181-250
Telefax +49 211 6181-241
E-Mail j.kuerten@gerresheimer.com
Internet www.gerresheimer.com

of excluding shareholders' subscription rights, creating new conditional capital and correspondingly amending section 4 (5) of the Articles of Association.

The following shareholder representatives were reelected to the Supervisory Board:

- Andrea Abt
- Dr. Karin Dorrepaal
- Dr. Axel Herberg
- Dr. Peter Noé
- Theodor Stuth
- Udo J. Vetter

At the ensuing Supervisory Board meeting, Dr. Axel Herberg was reelected as Chairman of the Supervisory Board.

At today's Annual General Meeting, 77.66% of the capital stock was represented. The detailed voting results on all items of the Annual General Meeting agenda are available here:

www.gerresheimer.com/en/investor-relations/annual-general-meeting

The speech delivered at the Annual General Meeting is available here:

www.gerresheimer.com/en/investor-relations/annual-general-meeting

The Annual Report is available here:

www.gerresheimer.com/en/investor-relations/reports

About Gerresheimer

Gerresheimer is a leading global partner to the pharma and healthcare industries. The company's special glass and plastic products contribute to health and well-being. Gerresheimer is a global organization with about 10.000 employees and manufacturing operations in the local markets, close to customers. With plants in Europe, North and South America and Asia Gerresheimer generates revenues of approximately EUR 1.4 billion. The comprehensive product portfolio includes pharmaceutical packaging products as well as convenient and safe drug delivery systems such as insulin pens, inhalers, pre-fillable syringes, vials, ampoules, bottles and containers for liquid and solid pharmaceuticals with closure and safety systems, plus cosmetic packaging products.

Press contact

Jens Kürten
Group Senior Director Communication & Marketing
Phone +49 211 6181-250
Fax +49 211 6181-241
E-Mail j.kuerten@gerresheimer.com

Investor Relations contact

Severine Camp
Corporate Senior Director Investor Relations
Phone +49 211 6181-314
Fax +49 211 6181-121
E-Mail s.camp@gerresheimer.com